The American Society of Nephrology – Kidney Week 2017 (ASN 2017) congress takes place October 31st to November 5th 2017 in New Orleans. In this article, the COMPACT RENAL team has highlighted key sessions and posters relating to hyperkalemia.
Note that hyperlinks to symposia will take you to the ASN Kidney Week website, where you will have the option to add sessions to your calendar. Links in  point to abstracts.
Thursday 2 November
An industry symposium at 12:45pm in the Hilton Riverside, Grand Ballroom A, will provide an overview of the prevalence, underlying causes, and risk factors for hyperkalemia, presented by Biff Palmer, USA. Matthew Weir, USA will describe approaches to allow continuation of RAAS blockade in Diabetes or Heart Failure patients and hyperkalemia.
At 2pm in Room 273, a basic/clinical science session entitled Integrated Effects of Potassium and Aldosterone in Controlling Potassium Excretion, will feature presentations from David Ellison, USA, Sebastian Bachmann, Germany, Paul Welling, USA and Laurence Palmer, USA on the physiology of potassium excretion.
- A real-world data analysis on patient outcomes in 268 ESRD (End Stage Renal Disease) on hemodialysis, which showed treatment with patiromer lowers serum potassium (sK) levels in real-world settings, with the greatest effect among patients with sK >6.5mEq/L:
“Outcomes in ESRD Patients on Hemodialysis Taking Patiromer for Hyperkalemia [TH-PO779]
- An analysis of 1,379 patients from a large US dialysis provider, which showed multiple hyperkalemia episodes and a recent SPS order were associated with patiromer initiation:
“Patients Characteristics and Correlates of Patiromer Initiation for Hyperkalemia in Hemodialysis”[TH-PO780]
- An open-label Phase III study in 751 outpatients showed sodium zirconium cyclosilicate rapidly reduced potassium levels in patients with hyperkalemia: “Maintained Efficacy and Safety of Sodium Zirkonium Cyclosilicate for Hyperkalemia: 12-Month, Open-Label, Phase 3 Study” [TH-PO1112]
- A post-hoc subgroup analysis of a Phase III study in 126/751 patients showed oral outpatient treatment with sodium zirconium cyclosilicate rapidly normalized K+ in patients with baseline K+ ≥6.0mEq/L with few adverse events: “Acute Efficacy of Sodium Zirconium Cyclosilicate for Hyperkalemia in Outpatients with Potassium ≥6.0mEq/L: Post-Hoc Subgroup Analysis of Phase 3 Study”[TH-PO1113]
Friday 3 November
At 4.30pm, two oral abstracts will be presented in different sessions. In the Mineral Disease: FGF23 and Mineral Metabolism session, David Bushinsky, USA will present on the effects of the potassium binder patiromer on markers of mineral metabolism [FR-OR068]. In the CKD-CV Axis: Epidemiology and Outcomes session, Roberto Pecoits-Filho, Australia will present data from CKDopps suggesting RAASi therapies may be underused, particularly in the US [FR-OR018].There is also a late-breaking poster presentation on Friday: Efficacy and Safety of Short-Term Treatment with Sodium Zirconium Cyclosilicate (ZS-9) for Hyperkalemia: Open-Label, Phase III Trial [FR-PO1074]
Saturday 4 November
Several posters on Saturday will focus on hyperkalemia, with key highlights including:
- A matching-adjusted indirect comparison of patient-level data from Phase IIII studies comparing sodium zirconium cyclosilicate and patiromer [SA-PO434]: Indirect Comparison of Sodium Zirkonium Cyclosilicate versus Patiromer in the Treatment of Hyperkalemia through 48 hours
- Data from the medical records of 91,709 patients hospitalized over 24 months showed that high potassium is common in hospitalized patients and associated with high mortality [SA-PO046]
Sunday 5 November
We have not identified any hyperkalemia-related sessions on Sunday.
We wish you a safe journey to New Orleans and we look forward to reporting back from the congress on the key presentations.